Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish Heart Failure Registry

Heart Failure

Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes

Diabetes Res Clin Pract

Kokura Y, Kishimori T, Kato T, Iwasaki Y, Wada A, Tani A, Yamaji R, Koike J, Matsumoto T, Yagi T, Sekine O, Okada M

doi: 10.1016/j.diabres.2026.113404

Atrial Fibrillation

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

Clin Res Cardiol

Menichelli D, Gazzaniga G, Poli D, Palareti G, Antonucci E, Pani A, Pignatelli P, Pastori D, START2 Register Investigators

doi: 10.1007/s00392-025-02765-7

Heart Failure

Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes

JACC Heart Fail

Harrington J, Giczewska A, Rao VN, Fudim M, Peters AE, Chrischilles E, Jones WS, May H, Steinberg BA, VanWormer J, Cyr DD, Felker GM

doi: 10.1016/j.jchf.2025.102768

Cardiovascular Risk and Diseases

On target? Cardiovascular risk factor patterns in type 1 and type 2 diabetes: Real-world attainment of cardiovascular risk factor targets and use of medication

Diabetes Res Clin Pract

Lit VF, Bak JCG, van Bon AC, Serné EH, Sijstermans K, Brouwer CB, Eland IA, Stouthart PJHM, van Bemmel T, Groenwold RHH, Sas TCJ, Verheugt CL

doi: 10.1016/j.diabres.2026.113440

Heart Failure

Incidence, medical therapy, and outcomes in heart failure with improved ejection fraction across guideline definitions

Am Heart J

Agharahmanian A, Min KH, Go AS, Parikh RV, Ambrosy AP, Tan TC, Svetlichnaya J, Vardeny O, Solomon SD, Inciardi RM, Vaduganathan M, Sandhu AT, Ku IA, Bhatt AS

doi: 10.1016/j.ahj.2026.107595

Cardiovascular Risk and Diseases

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Diabetes Obes Metab

Ni J, Chen L, Su H, Cai J, Wang C, Lu W, Wang Y, Lu J, Xia T, Zhou J

doi: 10.1111/dom.70214

Heart Failure

Performance of prediction models for incident heart failure and heart failure hospitalization in individuals with type 2 diabetes: a systematic review and meta-analysis

Eur J Heart Fail

Mircescu A, Allan W, Haris M, Hurdus B, Helbitz A, Ginks W, Wu J, Sattar N, Petrie MC, Ajjan R, Nadarajah R, Gale CP

doi: 10.1093/ejhf/xuag090

Heart Failure

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

Eur J Heart Fail

Ameri P, Costa P, Benson L, Stolfo D, Sayour NV, Ljungman C, Butler J, Anker SD, Girerd N, Keramida K, Filippatos G, Lund LH, Lindberg F, Savarese G

doi: 10.1002/ejhf.3775

Heart Failure

Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

Eur J Heart Fail

Adamo M, Pagnesi M, Chioncel O, Bayes-Genis A, Abdelhamid M, Antohi EL, Bucciarelli-Ducci C, Chieffo A, Cosyns B, Gilard M, Grapsa J, González A, Gustafsson F, Iung B, Joner M, Karam N, Lund LH, Maisano F, Moura B, Praz F, Rudolph TK, Sannino A, Savarese G, Tocchetti CG, Van Empel VPM, Volterrani M, Windecker S, Ponikowski P, Rosano GMC, Barbato E, Metra M

doi: 10.1002/ejhf.70023

Related content

Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes

On target? Cardiovascular risk factor patterns in type 1 and type 2 diabetes: Real-world attainment of cardiovascular risk factor targets and use of medication

Incidence, medical therapy, and outcomes in heart failure with improved ejection fraction across guideline definitions

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Performance of prediction models for incident heart failure and heart failure hospitalization in individuals with type 2 diabetes: a systematic review and meta-analysis

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC